The enhanced NAD+ availability and improved mitochondrial function in muscle cells may actually support muscle maintenance and recovery
MOTS-c AMPK
(Source: Novo Nordisk) In September 2024: Eli Lilly reported positive Phase 3 results for retatrutide, a novel triple GLP-1/GIP/glucagon receptor agonist, demonstrating an average weight loss of 24.2% at 48 weeks in adults with obesity, representing the highest weight loss achieved with any pharmacological agent to date and approaching bariatric surgery efficacy
14 , 15 , 46 The popularity of these nanoparticles stems from their improved compatibility with the body, cost-effectiveness, safety, and effectiveness
However, treatment response varies considerably between individuals, and several factors can influence effectiveness
The at-home injection format provides both convenience and flexibility, allowing you to manage your weight loss journey on your own terms